PubMed Health⌕ Search

Biomedical subjects

Jorge Soto

Publications and source records attributed to Jorge Soto.

6 recordsLinked to original sources

Length of stay by route of contrast administration for diagnosis of appendicitis by computed-tomography scan.

OBJECTIVES: Studies show equivalent accuracy of abdominal computed tomography (CT) using rectal contrast compared with oral contrast for diagnosing appendicitis. The authors evaluated whether emergency department (ED) length of stay and satisfaction differed by route of contrast administration for abdominal CT. METHODS: This before-and-after intervention evaluated adult patients in an urban academic ED who were undergoing abdominal CT to screen for suspected appendicitis. Phase 1 subjects had a CT after oral contrast. Phase 2 patients had a CT after rectal contrast infused by gravity drip. Patients were interviewed after CT scan to assess satisfaction and discomfort. The primary outcome was ED length of stay. Medians, 95% binomial confidence intervals (CI), and Wilcoxon rank sum test of differences were calculated. RESULTS: One hundred twelve patients were enrolled; half received rectal contrast. There was a significant decrease in length of stay for patients who were administered rectal contrast (261 min, 95% CI = 236 to 305 min) vs. oral contrast (332 min, 95% CI = 299 to 362 min), p = 0.009. Although subjects in the rectal-contrast group waited 65 minutes longer than did oral-contrast patients before receiving contrast after the CT order, the time from contrast administration to CT was 13 minutes, vs. 150 minutes for patients receiving oral contrast (p < 0.001). Patient satisfaction and discomfort did not differ by route of contrast administration. CONCLUSIONS: Rectal contrast for patients undergoing abdominal CT to rule out appendicitis reduced ED length of stay by more than an hour and did not affect patient satisfaction or discomfort. Rectal-contrast administration for abdominal CT may significantly shorten patient throughput time for individuals undergoing evaluation for appendicitis.

Adult↗

[Cancer pharmacogenetics: study of genetically determined variations on cancer susceptibility due to xenobiotic exposure].

Pharmacogenetics is the study of genetically determined variations in the response to drugs and toxic agents, and their implications on disease. Recently, the discipline has acquired great relevancy due to the development of non-invasive molecular techniques that identify genetic variants in human beings. There is also a need to explain the individual differences in susceptibility to drug actions and disease risk. Genetic variants can modify the magnitude of a pharmacologic effect, toxicity threshold, secondary effects and drug interactions. There are approximately thirty families of drug-metabolizing enzymes with genetic variants that cause functional alterations and variations in pharmacologic activity. We summarize the general knowledge about genetic variants of biotransformation enzymes, their relationship with cancer risk and the role of ethnicity. Cancer pharmacogenetics is another promising and exciting research area that will explain why people with an almost identical group of genes, have a different susceptibility to cancer, whose etiology has genetic and environmental components.

Aryl Hydrocarbon Hydroxylases↗

Virtual colonoscopy.

Explore the source record for details and available documents.

Colonography, Computed Tomographic↗

Divalent ansa-zirconocenes: stereoselective synthesis and high activity for propylene polymerization.

The reduction of ZrCl4(PR3)2 with Li powder, in the presence of a stoichiometric amount of trans-1,4-diphenyl-1,3-butadiene, affords the Zr(II) diene complexes (1) in 90-93% yields. This reaction consists of a rate-limiting step for the formation of the chloride-bridged Zr(III) dimer (2) and a fast diene-driven disproportionation of 2 to 1 and ZrCl4(PR3)2 that re-enters the reduction cycle. The reaction of 1 with Li2{Me2Si(2-Me-4-Ph-Ind)2} in toluene produces quantitatively the desired racemic, divalent ansa-zirconocene (3) that is a highly active isospecific propylene polymerization catalyst upon activation with common activators.

Journal Article↗